PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32546645-1	2020	PURPOSE: In the S-TRAC trial, adjuvant sunitinib improved disease-free survival (DFS) compared with placebo in patients with loco-regional renal cell carcinoma (RCC) at high risk of recurrence.	Sunitinib	39-48	T cell receptor alpha constant	Homo sapiens	18-22	
29374054-1	2018	Purpose: Adjuvant sunitinib therapy compared with placebo prolonged disease-free survival (DFS) in patients with locoregional high-risk renal cell carcinoma (RCC) in the S-TRAC trial (ClinicalTrials.gov number NCT00375674).	Sunitinib	18-27	T cell receptor alpha constant	Homo sapiens	172-176	
31922424-3	2020	In November 2017, sunitinib was approved in the USA as the first adjuvant therapy for patients at high risk for recurrent RCC postnephrectomy based on results from the S-TRAC trial.	Sunitinib	18-27	T cell receptor alpha constant	Homo sapiens	170-174	
31348025-7	2019	Based on the S-TRAC data, sunitinib is approved for use in the adjuvant setting, and can be considered under select circumstances.	Sunitinib	26-35	T cell receptor alpha constant	Homo sapiens	15-19	
30401688-1	2019	PURPOSE: In the S-TRAC trial, adjuvant sunitinib prolonged disease-free survival (DFS) versus placebo in patients with loco-regional renal cell carcinoma at high risk of recurrence after nephrectomy.	Sunitinib	39-48	T cell receptor alpha constant	Homo sapiens	18-22	
30412222-2	2018	We report safety, therapy management, and patient-reported outcomes for patients receiving sunitinib and placebo in the S-TRAC trial.	Sunitinib	91-100	T cell receptor alpha constant	Homo sapiens	122-126	
29877179-6	2018	In contrast, the S-TRAC trial showed improved DFS after one year of adjuvant sunitinib using central review process, but not using investigator review process.	Sunitinib	77-86	T cell receptor alpha constant	Homo sapiens	19-23	
32947305-4	2020	Evidence supporting the use of these therapies in the adjuvant setting is mixed, although one clinical trial, S-TRAC, has shown improvements in disease-free survival with 1 year of adjuvant sunitinib among patients with clear cell histology and high-risk features, leading to the first US Food and Drug Administration approval of an adjuvant therapy for high-risk RCC patients.	Sunitinib	190-199	T cell receptor alpha constant	Homo sapiens	112-116	
31054006-3	2019	The S-TRAC study demonstrated a statistically significant improvement in disease-free survival (DFS) of greater than 1 year with adjuvant sunitinib compared to placebo in patients with high-risk localized RCC and earned it FDA approval.	Sunitinib	138-147	T cell receptor alpha constant	Homo sapiens	6-10	
28479237-16	2018	S-TRAC provides evidence that 1 year of adjuvant sunitinib in patients with higher risk locoregional disease increases the median time to recurrence.	Sunitinib	49-58	T cell receptor alpha constant	Homo sapiens	2-6	
29662544-6	2017	Sunitinib has also been tested in the adjuvant setting, within the ASSURE and S-TRAC trials, with opposite results; indeed, equivocal risk-stratification criteria, as well as immature overall survival (OS) data prevent any definitive conclusion on this important issue.	Sunitinib	0-9	T cell receptor alpha constant	Homo sapiens	80-84	
27930642-4	2016	In a phase 3 adjuvant therapy trial (S-TRAC), sunitinib increased median disease-free survival in patients with clear cell RCC who were at very high risk.	Sunitinib	46-55	T cell receptor alpha constant	Homo sapiens	39-43